Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

AMIODARONE HCL

All products: general benefit

Other products in the same Health Canada class (C01B) — coverage varies; not interchangeable

  • Disopyramide (Norpace): general benefit, Not a benefit, Listing status unconfirmed
  • Flecainide (Tambocor): general benefit, Not a benefit
  • Mexiletine (Mexitil): general benefit, Not a benefit
  • Propafenone (Rythmol): general benefit

Amiodarone · DIN 02385465 · 200mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Amiodarone · DIN 02385465 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-10 · brand AMIODARONE · ATC C01BD01 AMIODARONE · form Tablet · route Oral · ingredients AMIODARONE HYDROCHLORIDE 200 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Amiodarone: Formulary list price $0.3706/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3706 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87109 · Verify on the e-Formulary ↗ (DIN 02385465)

Source record
DIN 02385465: Amiodarone Raw flags: chronicUseMed=Y, sec3=Y Item: 240400072; group id 273; item number 0565; lccId None; manufacturer id SIV Source form: Tab; strength: 200mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3706; ministry $0.3706 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385465 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87109 Therapeutic Notes (formulary) The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
Interchangeable products
Amiodarone · DIN 02364336 · $0.3706 Apo-Amiodarone · DIN 02246194 · $0.3706 Cordarone · DIN 02036282 · not recorded Jamp Amiodarone · DIN 02531844 · $0.3706 PMS-Amiodarone · DIN 02242472 · $0.3706 Riva-Amiodarone · DIN 02247217 · $0.3706 Sandoz Amiodarone · DIN 02243836 · $0.3706 Teva-Amiodarone · DIN 02239835 · $0.3706
Shortage status: resolved shortage (ended 2020-12-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap

PROPAFENONE HCL

· 6 products · General benefit · strengths: 150mg, 300mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications Considering its potential for life-threatening side effects and the substantial management difficulties associated with its oral use, TEVA-AMIODARONE (amiodarone hydrochloride) is indicated only for the treatment of patients with the following documented life-threatening, recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics, or when alternative agents could not be tolerated: • Hemodynamically unstable ventricular tachycardia (VT). • Recurrent ventricular fibrillation (VF). As is the case for other antiarrhythmic agents, there is no evidence from controlled clinical trials that the use of amiodarone hydrochloride tablets favourably affects survival. Because the life-threatening nature of arrhythmias treated, potential interaction with prior therapy, and potential exacerbation of arrhythmia, initiation of therapy with TEVA- AMIODARONE should be carried out in the hospital. TEVA-AMIODARONE should be used only by healthcare professionals familiar with and with access to (directly or referral) the use of all available modalities for treating recurrent life- threatening ventricular ar… https://pdf.hres.ca/dpd_pm/00084740.PDF PM date: 2026-05-13 Source product: TEVA-AMIODARONE; DIN 02239835; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.